C2N and Eisai Collaborate to Build Awareness and Real-World

C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings

/PRNewswire/ -- C2N Diagnostics and Eisai Inc. today announced the Companies have entered into a memorandum of understanding that will seek to build awareness...

Related Keywords

Australia , New Zealand , Russia , Ivan Cheung , Libby Holman , Adam Shapiro , Joel Braunstein , Milken Institute , Linkedin , Eisai Inc , Eisai Europe Ltd , Eisai Co Ltd , Alzheimer Disease International , Biomarkers For Cognition Health , United Nations Sustainable Development Goals Sdgs , Global Alzheimer , Disease Officer , Senior Corporate Officer , Its Blood Based Biomarkers , Clarity Through Innovation , P Tau Multi Analyte Assay , United Nations Sustainable Development Goals , Middle East , World Alzheimer Report , Building Workforce Capacity , Improve Detection ,